Global Ioversol
Global Ioversol

Ioversol Comprehensive Study by Type (Ioversol 34% Injectable Solution (Optiray 160), Ioversol 51% Injectable Solution (Optiray 240), Ioversol 64% Injectable Solution (Optiray 300), Ioversol 68% Injectable Solution (Optiray 320), Ioversol 74% Injectable Solution (Optiray 350)), Application (X-Ray, CT Scan, Brain Disorders, Blood Vessel Disorders, Heart Disorders, Others) Players and Region - Global Market Outlook to 2024

Ioversol Market Segmented into XX Submarkets. | Forecast Years: 2019- 2024  

Oct 2019 Edition 238 Pages 200 Tables & Figures
  • Summary
  • Market Segments
  • Table of Content
  • List of Tables & Figures
  • Companies Mentioned
Global Ioversol Market Overview:
Ioversol is an organic compound used to allow various human body parts such as organs, blood vessels, and others to be seen more accurately thereby helping physicians in diagnosing various chronic diseases and bone injuries. It is available in different concentrations as well ranging from 240 to 350 mg of iodine per millimeter. Growing advancement in medical imaging technologies, and introduction of mobile medical imaging techniques provides huge boost to ioversol chemical. Some of the key players profiled in the study are Liebel-Flarsheim Company (United States), Guerbet (France), Jiangsu Hengrui Medicine (China) and Mallinckrodt Pharmaceuticals (United Kingdom).

On the basis of geography, the market of Ioversol has been segmented into South America (Brazil, Argentina, Rest of South America), Asia Pacific (China, Japan, India, South Korea, Taiwan, Australia, Rest of Asia-Pacific), Europe (Germany, France, Italy, United Kingdom, Netherlands, Rest of Europe), MEA (Middle East, Africa), North America (United States, Canada, Mexico).

Market Drivers
  • Growing Number of Chronic Diseases and Bone Disorders
  • Increasing Geriatric Population Leading to Rise in Prevalence of Diseases

Market Trend
  • Need for Proper Prescription of Doctor Before Use of Ioversol

Restraints
  • Ill-effect Associated with Over Consumption of Ioversol
  • Lack of Research About Use of Ioversol Limits Its Application

Opportunities
  • Technological Advancement in Medical Imaging Techniques
  • Increasing Healthcare Spending in Emerging Countries

Challenges
  • Precautions Required Before Ioversol Injection
  • Stringent Regulatory Frameworks Related to Ioversol Chemical



Food and Drug Administration (FDA) regulates the use of Ioversol, dosages as per age, and usage for specific populations. The body also mandates manufacturers to apply RFID-Tagged syringe directions for use.

Target Audience:
Ioversol Manufacturers, Raw Materials Suppliers/Distributors, End-users Industries, Market Research and Consulting Firms, Potential Investors and Others

Major Objectives Focused through this Study
• To define, describe, and forecast the Global Ioversol market on the basis of product [Ioversol 34% Injectable Solution (Optiray 160), Ioversol 51% Injectable Solution (Optiray 240), Ioversol 64% Injectable Solution (Optiray 300), Ioversol 68% Injectable Solution (Optiray 320) and Ioversol 74% Injectable Solution (Optiray 350)] , application [X-Ray, CT Scan, Brain Disorders, Blood Vessel Disorders, Heart Disorders and Others], key regions and end user
• To provide in-depth information regarding major influencing factors affecting the growth of the market (trends, drivers, restraints, opportunities, and industry-centric and regional challenges)
• To strategically analyse the micro-markets and important business segments with respect to individual growth drivers , market trends and potential, and historical contributions to the total market
• Identifying the opportunities in the market for key stakeholders and detailing the competitive landscape for market leaders
• To provide market size for various segments of the Ioversol market with respect to major geographies, namely, South America (Brazil, Argentina, Rest of South America), Asia Pacific (China, Japan, India, South Korea, Taiwan, Australia, Rest of Asia-Pacific), Europe (Germany, France, Italy, United Kingdom, Netherlands, Rest of Europe), MEA (Middle East, Africa), North America (United States, Canada, Mexico)
• To strategically profile the key players and analyzing their market shares and core competencies in the Ioversol industry
• To track key developments such as product launches, expansions, agreements, partnerships, mergers & acquisitions, and R&D activities that are key factors in shaping the market

Available Customization:
Data related to EXIM [Export- Import], production & consumption by country or regional level break-up can be provided based on client request**. Additionally, the Vendors which are also part of the research are China Resources Pharmaceutical (Shanghai) Co, (China), Novalek Pharmaceuticals Pvt. Ltd (India), Stellence Pharmscience Pvt. Ltd (India) and A.S. Joshi & Company (India).
** Confirmation on availability of data would be informed prior purchase

While framing the research framework, major and emerging players operating in the Ioversol market in various regions have been profiled, and their offerings, geographic footprints, and distribution/sales channels have been analysed through in-depth discussions. Top-down and bottom-up approaches have been used to determine the overall market size. Sizes of the other individual markets have been estimated using the percentage splits obtained through secondary sources such as Hoovers, Bloomberg BusinessWeek, and Dow Jones (Factiva), along with primary respondents. The complete methodology includes the study of the annual and financial reports of the key market players and extensive interviews with industry experts such as CEOs, VPs, directors, and marketing executives for key insights (both qualitative and quantitative) related to the market.
Report Objectives / Segmentation Covered
By Type
  • Ioversol 34% Injectable Solution (Optiray 160)
  • Ioversol 51% Injectable Solution (Optiray 240)
  • Ioversol 64% Injectable Solution (Optiray 300)
  • Ioversol 68% Injectable Solution (Optiray 320)
  • Ioversol 74% Injectable Solution (Optiray 350)
By Application
  • X-Ray
  • CT Scan
  • Brain Disorders
  • Blood Vessel Disorders
  • Heart Disorders
  • Others
By Regions
  • South America
    • Brazil
    • Argentina
    • Rest of South America
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Taiwan
    • Australia
    • Rest of Asia-Pacific
  • Europe
    • Germany
    • France
    • Italy
    • United Kingdom
    • Netherlands
    • Rest of Europe
  • MEA
    • Middle East
    • Africa
  • North America
    • United States
    • Canada
    • Mexico
  • 1. Market Overview
    • 1.1. Introduction
    • 1.2. Scope/Objective of the Study
      • 1.2.1. Research Objective
  • 2. Executive Summary
    • 2.1. Introduction
  • 3. Market Dynamics
    • 3.1. Introduction
    • 3.2. Market Drivers
      • 3.2.1. Growing Number of Chronic Diseases and Bone Disorders
      • 3.2.2. Increasing Geriatric Population Leading to Rise in Prevalence of Diseases
    • 3.3. Market Challenges
      • 3.3.1. Precautions Required Before Ioversol Injection
      • 3.3.2. Stringent Regulatory Frameworks Related to Ioversol Chemical
    • 3.4. Market Trends
      • 3.4.1. Need for Proper Prescription of Doctor Before Use of Ioversol
  • 4. Market Factor Analysis
    • 4.1. Porters Five Forces
    • 4.2. Supply/Value Chain
    • 4.3. PESTEL analysis
    • 4.4. Market Entropy
    • 4.5. Patent/Trademark Analysis
  • 5. Global Ioversol, by Type, Application and Region (value) (2013-2018)
    • 5.1. Introduction
    • 5.2. Global Ioversol (Value)
      • 5.2.1. Global Ioversol by: Type (Value)
        • 5.2.1.1. Ioversol 34% Injectable Solution (Optiray 160)
        • 5.2.1.2. Ioversol 51% Injectable Solution (Optiray 240)
        • 5.2.1.3. Ioversol 64% Injectable Solution (Optiray 300)
        • 5.2.1.4. Ioversol 68% Injectable Solution (Optiray 320)
        • 5.2.1.5. Ioversol 74% Injectable Solution (Optiray 350)
      • 5.2.2. Global Ioversol by: Application (Value)
        • 5.2.2.1. X-Ray
        • 5.2.2.2. CT Scan
        • 5.2.2.3. Brain Disorders
        • 5.2.2.4. Blood Vessel Disorders
        • 5.2.2.5. Heart Disorders
        • 5.2.2.6. Others
      • 5.2.3. Global Ioversol Region
        • 5.2.3.1. South America
          • 5.2.3.1.1. Brazil
          • 5.2.3.1.2. Argentina
          • 5.2.3.1.3. Rest of South America
        • 5.2.3.2. Asia Pacific
          • 5.2.3.2.1. China
          • 5.2.3.2.2. Japan
          • 5.2.3.2.3. India
          • 5.2.3.2.4. South Korea
          • 5.2.3.2.5. Taiwan
          • 5.2.3.2.6. Australia
          • 5.2.3.2.7. Rest of Asia-Pacific
        • 5.2.3.3. Europe
          • 5.2.3.3.1. Germany
          • 5.2.3.3.2. France
          • 5.2.3.3.3. Italy
          • 5.2.3.3.4. United Kingdom
          • 5.2.3.3.5. Netherlands
          • 5.2.3.3.6. Rest of Europe
        • 5.2.3.4. MEA
          • 5.2.3.4.1. Middle East
          • 5.2.3.4.2. Africa
        • 5.2.3.5. North America
          • 5.2.3.5.1. United States
          • 5.2.3.5.2. Canada
          • 5.2.3.5.3. Mexico
  • 6. Ioversol: Manufacturers/Players Analysis
    • 6.1. Competitive Landscape
      • 6.1.1. Market Share Analysis
    • 6.2. Peer Group Analysis (2018)
    • 6.3. BCG Matrix
    • 6.4. Company Profile
      • 6.4.1. Liebel-Flarsheim Company (United States)
        • 6.4.1.1. Business Overview
        • 6.4.1.2. Products/Services Offerings
        • 6.4.1.3. Financial Analysis
        • 6.4.1.4. SWOT Analysis
      • 6.4.2. Guerbet (France)
        • 6.4.2.1. Business Overview
        • 6.4.2.2. Products/Services Offerings
        • 6.4.2.3. Financial Analysis
        • 6.4.2.4. SWOT Analysis
      • 6.4.3. Jiangsu Hengrui Medicine (China)
        • 6.4.3.1. Business Overview
        • 6.4.3.2. Products/Services Offerings
        • 6.4.3.3. Financial Analysis
        • 6.4.3.4. SWOT Analysis
      • 6.4.4. Mallinckrodt Pharmaceuticals (United Kingdom)
        • 6.4.4.1. Business Overview
        • 6.4.4.2. Products/Services Offerings
        • 6.4.4.3. Financial Analysis
        • 6.4.4.4. SWOT Analysis
  • 7. Global Ioversol Sale, by Type, Application and Region (value) (2019-2024)
    • 7.1. Introduction
    • 7.2. Global Ioversol (Value)
      • 7.2.1. Global Ioversol by: Type (Value)
        • 7.2.1.1. Ioversol 34% Injectable Solution (Optiray 160)
        • 7.2.1.2. Ioversol 51% Injectable Solution (Optiray 240)
        • 7.2.1.3. Ioversol 64% Injectable Solution (Optiray 300)
        • 7.2.1.4. Ioversol 68% Injectable Solution (Optiray 320)
        • 7.2.1.5. Ioversol 74% Injectable Solution (Optiray 350)
      • 7.2.2. Global Ioversol by: Application (Value)
        • 7.2.2.1. X-Ray
        • 7.2.2.2. CT Scan
        • 7.2.2.3. Brain Disorders
        • 7.2.2.4. Blood Vessel Disorders
        • 7.2.2.5. Heart Disorders
        • 7.2.2.6. Others
      • 7.2.3. Global Ioversol Region
        • 7.2.3.1. South America
          • 7.2.3.1.1. Brazil
          • 7.2.3.1.2. Argentina
          • 7.2.3.1.3. Rest of South America
        • 7.2.3.2. Asia Pacific
          • 7.2.3.2.1. China
          • 7.2.3.2.2. Japan
          • 7.2.3.2.3. India
          • 7.2.3.2.4. South Korea
          • 7.2.3.2.5. Taiwan
          • 7.2.3.2.6. Australia
          • 7.2.3.2.7. Rest of Asia-Pacific
        • 7.2.3.3. Europe
          • 7.2.3.3.1. Germany
          • 7.2.3.3.2. France
          • 7.2.3.3.3. Italy
          • 7.2.3.3.4. United Kingdom
          • 7.2.3.3.5. Netherlands
          • 7.2.3.3.6. Rest of Europe
        • 7.2.3.4. MEA
          • 7.2.3.4.1. Middle East
          • 7.2.3.4.2. Africa
        • 7.2.3.5. North America
          • 7.2.3.5.1. United States
          • 7.2.3.5.2. Canada
          • 7.2.3.5.3. Mexico
  • 8. Appendix
    • 8.1. Acronyms
  • 9. Methodology and Data Source
    • 9.1. Methodology/Research Approach
      • 9.1.1. Research Programs/Design
      • 9.1.2. Market Size Estimation
      • 9.1.3. Market Breakdown and Data Triangulation
    • 9.2. Data Source
      • 9.2.1. Secondary Sources
      • 9.2.2. Primary Sources
    • 9.3. Disclaimer
List of Tables
  • Table 1. Ioversol: by Type(USD Million)
  • Table 2. Ioversol Ioversol 34% Injectable Solution (Optiray 160) , by Region USD Million (2013-2018)
  • Table 3. Ioversol Ioversol 51% Injectable Solution (Optiray 240) , by Region USD Million (2013-2018)
  • Table 4. Ioversol Ioversol 64% Injectable Solution (Optiray 300) , by Region USD Million (2013-2018)
  • Table 5. Ioversol Ioversol 68% Injectable Solution (Optiray 320) , by Region USD Million (2013-2018)
  • Table 6. Ioversol Ioversol 74% Injectable Solution (Optiray 350) , by Region USD Million (2013-2018)
  • Table 7. Ioversol: by Application(USD Million)
  • Table 8. Ioversol X-Ray , by Region USD Million (2013-2018)
  • Table 9. Ioversol CT Scan , by Region USD Million (2013-2018)
  • Table 10. Ioversol Brain Disorders , by Region USD Million (2013-2018)
  • Table 11. Ioversol Blood Vessel Disorders , by Region USD Million (2013-2018)
  • Table 12. Ioversol Heart Disorders , by Region USD Million (2013-2018)
  • Table 13. Ioversol Others , by Region USD Million (2013-2018)
  • Table 14. South America Ioversol, by Country USD Million (2013-2018)
  • Table 15. South America Ioversol, by Type USD Million (2013-2018)
  • Table 16. South America Ioversol, by Application USD Million (2013-2018)
  • Table 17. Brazil Ioversol, by Type USD Million (2013-2018)
  • Table 18. Brazil Ioversol, by Application USD Million (2013-2018)
  • Table 19. Argentina Ioversol, by Type USD Million (2013-2018)
  • Table 20. Argentina Ioversol, by Application USD Million (2013-2018)
  • Table 21. Rest of South America Ioversol, by Type USD Million (2013-2018)
  • Table 22. Rest of South America Ioversol, by Application USD Million (2013-2018)
  • Table 23. Asia Pacific Ioversol, by Country USD Million (2013-2018)
  • Table 24. Asia Pacific Ioversol, by Type USD Million (2013-2018)
  • Table 25. Asia Pacific Ioversol, by Application USD Million (2013-2018)
  • Table 26. China Ioversol, by Type USD Million (2013-2018)
  • Table 27. China Ioversol, by Application USD Million (2013-2018)
  • Table 28. Japan Ioversol, by Type USD Million (2013-2018)
  • Table 29. Japan Ioversol, by Application USD Million (2013-2018)
  • Table 30. India Ioversol, by Type USD Million (2013-2018)
  • Table 31. India Ioversol, by Application USD Million (2013-2018)
  • Table 32. South Korea Ioversol, by Type USD Million (2013-2018)
  • Table 33. South Korea Ioversol, by Application USD Million (2013-2018)
  • Table 34. Taiwan Ioversol, by Type USD Million (2013-2018)
  • Table 35. Taiwan Ioversol, by Application USD Million (2013-2018)
  • Table 36. Australia Ioversol, by Type USD Million (2013-2018)
  • Table 37. Australia Ioversol, by Application USD Million (2013-2018)
  • Table 38. Rest of Asia-Pacific Ioversol, by Type USD Million (2013-2018)
  • Table 39. Rest of Asia-Pacific Ioversol, by Application USD Million (2013-2018)
  • Table 40. Europe Ioversol, by Country USD Million (2013-2018)
  • Table 41. Europe Ioversol, by Type USD Million (2013-2018)
  • Table 42. Europe Ioversol, by Application USD Million (2013-2018)
  • Table 43. Germany Ioversol, by Type USD Million (2013-2018)
  • Table 44. Germany Ioversol, by Application USD Million (2013-2018)
  • Table 45. France Ioversol, by Type USD Million (2013-2018)
  • Table 46. France Ioversol, by Application USD Million (2013-2018)
  • Table 47. Italy Ioversol, by Type USD Million (2013-2018)
  • Table 48. Italy Ioversol, by Application USD Million (2013-2018)
  • Table 49. United Kingdom Ioversol, by Type USD Million (2013-2018)
  • Table 50. United Kingdom Ioversol, by Application USD Million (2013-2018)
  • Table 51. Netherlands Ioversol, by Type USD Million (2013-2018)
  • Table 52. Netherlands Ioversol, by Application USD Million (2013-2018)
  • Table 53. Rest of Europe Ioversol, by Type USD Million (2013-2018)
  • Table 54. Rest of Europe Ioversol, by Application USD Million (2013-2018)
  • Table 55. MEA Ioversol, by Country USD Million (2013-2018)
  • Table 56. MEA Ioversol, by Type USD Million (2013-2018)
  • Table 57. MEA Ioversol, by Application USD Million (2013-2018)
  • Table 58. Middle East Ioversol, by Type USD Million (2013-2018)
  • Table 59. Middle East Ioversol, by Application USD Million (2013-2018)
  • Table 60. Africa Ioversol, by Type USD Million (2013-2018)
  • Table 61. Africa Ioversol, by Application USD Million (2013-2018)
  • Table 62. North America Ioversol, by Country USD Million (2013-2018)
  • Table 63. North America Ioversol, by Type USD Million (2013-2018)
  • Table 64. North America Ioversol, by Application USD Million (2013-2018)
  • Table 65. United States Ioversol, by Type USD Million (2013-2018)
  • Table 66. United States Ioversol, by Application USD Million (2013-2018)
  • Table 67. Canada Ioversol, by Type USD Million (2013-2018)
  • Table 68. Canada Ioversol, by Application USD Million (2013-2018)
  • Table 69. Mexico Ioversol, by Type USD Million (2013-2018)
  • Table 70. Mexico Ioversol, by Application USD Million (2013-2018)
  • Table 71. Company Basic Information, Sales Area and Its Competitors
  • Table 72. Company Basic Information, Sales Area and Its Competitors
  • Table 73. Company Basic Information, Sales Area and Its Competitors
  • Table 74. Company Basic Information, Sales Area and Its Competitors
  • Table 75. Ioversol: by Type(USD Million)
  • Table 76. Ioversol Ioversol 34% Injectable Solution (Optiray 160) , by Region USD Million (2019-2024)
  • Table 77. Ioversol Ioversol 51% Injectable Solution (Optiray 240) , by Region USD Million (2019-2024)
  • Table 78. Ioversol Ioversol 64% Injectable Solution (Optiray 300) , by Region USD Million (2019-2024)
  • Table 79. Ioversol Ioversol 68% Injectable Solution (Optiray 320) , by Region USD Million (2019-2024)
  • Table 80. Ioversol Ioversol 74% Injectable Solution (Optiray 350) , by Region USD Million (2019-2024)
  • Table 81. Ioversol: by Application(USD Million)
  • Table 82. Ioversol X-Ray , by Region USD Million (2019-2024)
  • Table 83. Ioversol CT Scan , by Region USD Million (2019-2024)
  • Table 84. Ioversol Brain Disorders , by Region USD Million (2019-2024)
  • Table 85. Ioversol Blood Vessel Disorders , by Region USD Million (2019-2024)
  • Table 86. Ioversol Heart Disorders , by Region USD Million (2019-2024)
  • Table 87. Ioversol Others , by Region USD Million (2019-2024)
  • Table 88. South America Ioversol, by Country USD Million (2019-2024)
  • Table 89. South America Ioversol, by Type USD Million (2019-2024)
  • Table 90. South America Ioversol, by Application USD Million (2019-2024)
  • Table 91. Brazil Ioversol, by Type USD Million (2019-2024)
  • Table 92. Brazil Ioversol, by Application USD Million (2019-2024)
  • Table 93. Argentina Ioversol, by Type USD Million (2019-2024)
  • Table 94. Argentina Ioversol, by Application USD Million (2019-2024)
  • Table 95. Rest of South America Ioversol, by Type USD Million (2019-2024)
  • Table 96. Rest of South America Ioversol, by Application USD Million (2019-2024)
  • Table 97. Asia Pacific Ioversol, by Country USD Million (2019-2024)
  • Table 98. Asia Pacific Ioversol, by Type USD Million (2019-2024)
  • Table 99. Asia Pacific Ioversol, by Application USD Million (2019-2024)
  • Table 100. China Ioversol, by Type USD Million (2019-2024)
  • Table 101. China Ioversol, by Application USD Million (2019-2024)
  • Table 102. Japan Ioversol, by Type USD Million (2019-2024)
  • Table 103. Japan Ioversol, by Application USD Million (2019-2024)
  • Table 104. India Ioversol, by Type USD Million (2019-2024)
  • Table 105. India Ioversol, by Application USD Million (2019-2024)
  • Table 106. South Korea Ioversol, by Type USD Million (2019-2024)
  • Table 107. South Korea Ioversol, by Application USD Million (2019-2024)
  • Table 108. Taiwan Ioversol, by Type USD Million (2019-2024)
  • Table 109. Taiwan Ioversol, by Application USD Million (2019-2024)
  • Table 110. Australia Ioversol, by Type USD Million (2019-2024)
  • Table 111. Australia Ioversol, by Application USD Million (2019-2024)
  • Table 112. Rest of Asia-Pacific Ioversol, by Type USD Million (2019-2024)
  • Table 113. Rest of Asia-Pacific Ioversol, by Application USD Million (2019-2024)
  • Table 114. Europe Ioversol, by Country USD Million (2019-2024)
  • Table 115. Europe Ioversol, by Type USD Million (2019-2024)
  • Table 116. Europe Ioversol, by Application USD Million (2019-2024)
  • Table 117. Germany Ioversol, by Type USD Million (2019-2024)
  • Table 118. Germany Ioversol, by Application USD Million (2019-2024)
  • Table 119. France Ioversol, by Type USD Million (2019-2024)
  • Table 120. France Ioversol, by Application USD Million (2019-2024)
  • Table 121. Italy Ioversol, by Type USD Million (2019-2024)
  • Table 122. Italy Ioversol, by Application USD Million (2019-2024)
  • Table 123. United Kingdom Ioversol, by Type USD Million (2019-2024)
  • Table 124. United Kingdom Ioversol, by Application USD Million (2019-2024)
  • Table 125. Netherlands Ioversol, by Type USD Million (2019-2024)
  • Table 126. Netherlands Ioversol, by Application USD Million (2019-2024)
  • Table 127. Rest of Europe Ioversol, by Type USD Million (2019-2024)
  • Table 128. Rest of Europe Ioversol, by Application USD Million (2019-2024)
  • Table 129. MEA Ioversol, by Country USD Million (2019-2024)
  • Table 130. MEA Ioversol, by Type USD Million (2019-2024)
  • Table 131. MEA Ioversol, by Application USD Million (2019-2024)
  • Table 132. Middle East Ioversol, by Type USD Million (2019-2024)
  • Table 133. Middle East Ioversol, by Application USD Million (2019-2024)
  • Table 134. Africa Ioversol, by Type USD Million (2019-2024)
  • Table 135. Africa Ioversol, by Application USD Million (2019-2024)
  • Table 136. North America Ioversol, by Country USD Million (2019-2024)
  • Table 137. North America Ioversol, by Type USD Million (2019-2024)
  • Table 138. North America Ioversol, by Application USD Million (2019-2024)
  • Table 139. United States Ioversol, by Type USD Million (2019-2024)
  • Table 140. United States Ioversol, by Application USD Million (2019-2024)
  • Table 141. Canada Ioversol, by Type USD Million (2019-2024)
  • Table 142. Canada Ioversol, by Application USD Million (2019-2024)
  • Table 143. Mexico Ioversol, by Type USD Million (2019-2024)
  • Table 144. Mexico Ioversol, by Application USD Million (2019-2024)
  • Table 145. Research Programs/Design for This Report
  • Table 146. Key Data Information from Secondary Sources
  • Table 147. Key Data Information from Primary Sources
List of Figures
  • Figure 1. Porters Five Forces
  • Figure 2. Supply/Value Chain
  • Figure 3. PESTEL analysis
  • Figure 4. Global Ioversol: by Type USD Million (2013-2018)
  • Figure 5. Global Ioversol: by Application USD Million (2013-2018)
  • Figure 6. South America Ioversol Share (%), by Country
  • Figure 7. Asia Pacific Ioversol Share (%), by Country
  • Figure 8. Europe Ioversol Share (%), by Country
  • Figure 9. MEA Ioversol Share (%), by Country
  • Figure 10. North America Ioversol Share (%), by Country
  • Figure 11. Global Ioversol share by Players 2018 (%)
  • Figure 12. BCG Matrix for key Companies
  • Figure 13. Liebel-Flarsheim Company (United States) Revenue, Net Income and Gross profit
  • Figure 14. Liebel-Flarsheim Company (United States) Revenue: by Geography 2018
  • Figure 15. Guerbet (France) Revenue, Net Income and Gross profit
  • Figure 16. Guerbet (France) Revenue: by Geography 2018
  • Figure 17. Jiangsu Hengrui Medicine (China) Revenue, Net Income and Gross profit
  • Figure 18. Jiangsu Hengrui Medicine (China) Revenue: by Geography 2018
  • Figure 19. Mallinckrodt Pharmaceuticals (United Kingdom) Revenue, Net Income and Gross profit
  • Figure 20. Mallinckrodt Pharmaceuticals (United Kingdom) Revenue: by Geography 2018
  • Figure 21. Global Ioversol: by Type USD Million (2019-2024)
  • Figure 22. Global Ioversol: by Application USD Million (2019-2024)
  • Figure 23. South America Ioversol Share (%), by Country
  • Figure 24. Asia Pacific Ioversol Share (%), by Country
  • Figure 25. Europe Ioversol Share (%), by Country
  • Figure 26. MEA Ioversol Share (%), by Country
  • Figure 27. North America Ioversol Share (%), by Country
Some of the key companies/manufacturers profiled in the report
  • Liebel-Flarsheim Company (United States)
  • Guerbet (France)
  • Jiangsu Hengrui Medicine (China)
  • Mallinckrodt Pharmaceuticals (United Kingdom)
Additional players considered in the study are as follows:
China Resources Pharmaceutical (Shanghai) Co, (China) , Novalek Pharmaceuticals Pvt. Ltd (India) , Stellence Pharmscience Pvt. Ltd (India) , A.S. Joshi & Company (India)
Select License Type
Sample Report Enquiry Before Buy Request Discount

Speak with Analyst

Want to find out more about this report?

Get Free Consultation